Liver transplantation for hepatocellular carcinoma after yttrium therapy: a case report.
Yttrium-90 microspheres constitute one of the most recent treatment options for hepatocellular carcinoma (HCC) in the setting of cirrhosis. As such, their spectrum of indication is not yet fully established. Herein, we have reported the case of a patient with HCC beyond the listing criteria for liver transplantation (OLT) who was treated preoperatively with selective transarterial chemoembolization and yttrium-90 microspheres. He was subsequently transplanted with a liver from an 81-year-old donor allocated through Eurotransplant as a "rescue offer." The posttransplant course was uneventful. Pathologic examination revealed a multifocal, well-differentiated pT2 tumor with no vascular invasion. The patient is currently alive and in good condition at 14 months posttransplant, with no evidence of tumor recurrence by a current computed tomography scan. This report provided encouraging information on the potential of yttrium-90 microspheres as a bridging option before OLT for multifocal HCC.
Sotiropoulos
G C
GC
Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, Essen, Germany. sotiropoulos@ach.klinik.uni-mainz.de
Hilgard
P
P
Antoch
G
G
Nowak
K M
KM
Ertl
J
J
Fouzas
I
I
Molmenti
E P
EP
Sgourakis
G
G
Beckebaum
S
S
Paul
A
A
Broelsch
C E
CE
Lang
H
H
D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy* / Q000601:surgery* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000601:surgery* / Q000628:therapy; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D015021:Yttrium Radioisotopes